BIRC3 and BIRC5: multi-faceted inhibitors in cancer
Frazzi, Raffael. BIRC3 and BIRC5: multi-faceted inhibitors in cancer. Cell & Bioscience 11, Article number: 8(2021)
- Categories
- Reviews
Categories
Filter by Topics
1L therapy; bispecific antibodies Asthma Biomarkers Bladder Cancer Breast Cancer CAR-T-cells Circulating miRNAs diffuse large B-cell lymphoma DLBCL DLBCL COO Exosomes Extracellular Vesicles Fabry Disease FFPE Gene Expression Profiling HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Oncology Biomarker Panel Immune Response immuno-oncology agents Immunotherapy Kidney Liquid Biopsy Lupus miRNA Renal Disease Sub-typing targeted therapeutics2021
2020
A review of the use of Next Generation Sequencing methodologies to identify biomarkers of resistance to CKK4/6 inhibitors in ER+/HER2-breast cancer
Servetto, A., et al. A review of the use of Next Generation Sequencing methodologies to identify biomarkers of resistance to CKK4/6 inhibitors in ER+/HER2-breast cancer. Science Direct December 2020 DEC 9, 103191
- Categories
- Peer Reviewed Publications
- Reviews
Molecular, genomic and mutational landscape of oral leukoplakia
Farah, C. S. Molecular, genomic and mutational landscape of oral leukoplakia. Oral Diseases. 2020 AUG 3. DOI: 10.1111/odi.13608
- Categories
- Reviews
2017
Biomarkers for immunotherapy in bladder cancer: a moving target
Aggen, D., et al. Biomarkers for immunotherapy in bladder cancer: a moving target. 2017 Journal for ImmunoTherapy of Cancer 5:94
- Categories
- Reviews
Page last updated May 22, 2023